Updates are available Correction dated 2023-02-19
Click to view Correction: https://doi.org/10.1186/s13756-023-01217-z
-
Authors
van der Kooi, Tjallie
Sax, Hugo
Grundmann, Hajo
Pittet, Didier
de Greeff, Sabine
van Dissel, Jaap
Clack, Lauren
Wu, Albert W.
Davitt, Judith
Kostourou, Sofia
Maguinness, Alison
Michalik, Anna
Nedelcu, Viorica
Patyi, Márta
Perme Hajdinjak, Janja
Prosen, Milena
Tellez, David
Varga, Éva
Veini, Fani
Ziętkiewicz, Mirosław
Zingg, Walter
,
-
Funding
Funding for this research was provided by:
European Commission 7th Framework Programme
- License Information
-
More Information
Article History
Received: 9 May 2022
Accepted: 15 August 2022
First Online: 5 October 2022
Change Date: 19 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13756-023-01217-z
Declarations
:
: The Medical Ethical Research Committee of the Utrecht University Medical Center, Utrecht, the Netherlands, decided that the study was not subject to the Medical Research Involving Human Subjects Act. All institutional review boards of the study hospitals approved of the study protocol.
: Not applicable.
: HS served at the Swiss Federal Office of Public Health, Swissnoso (Nation center for Infection Prevention) and the World Health Organisation, received fee/honoraria for delivering training/lectures at Agfam, Switzerland; AstraZeneca; Walker Projects, Switzerland and the Digital Health Conference, Switzerland; participates in the Advisory board of Aseptuva and is CEO and owner of saxhealthdesign.com. JD is member of the data safety monitoring board of the SAFE trial (clinical study on treatment duration of S. aureus bacteraemias), unpaid. All the other authors have no competing interests to declare.
